Polycystic Kidney Diseases: Clinical Trials

50 trials for Polycystic Kidney Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 6 terminated, 5 recruiting, 5 unknown. 50 Phase 2, 12 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 250Completed 29, Terminated 6, Recruiting 5, Unknown 5, Active not recruiting 4, Enrolling by invitation 1
Phase 312Completed 5, Terminated 4, Unknown 2, Active not recruiting 1
Phase 12Completed 2

Follow Polycystic Kidney Diseases: new trials by email Literature Review of Polycystic Kidney Diseases trials Research Report on Polycystic Kidney Diseases

Trials (filtered) newest first · largest first

All 50 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bempedoic Acid Therapy for Polycystic Kidney Disease
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s) - ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Phase 2RecruitingKenneth Hallows1202026-09-012026-09-29
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
VX-407 - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2Active not recruitingVertex Pharmaceuticals Incorporated262025-11-192026-09-21
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ABBV-CLS-628, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2RecruitingCalico Life Sciences LLC2402025-06-092026-10-06
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JMKX003142 will be administered orally, Plcacebo - ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Phase 2RecruitingJemincare1352025-03-132025-07-03
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Tirzepatide, Placebo - Autosomal Dominant Polycystic Kidney, Obesity
Phase 2RecruitingUniversity of Colorado, Denver1262025-03-062025-05-06
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Empagliflozin, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedCantonal Hospital Graubuenden162024-09-012026-09-22
Study of Tamibarotene in Patients With ADPKD
Tamibarotene, Placebo - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2Active not recruitingRege Nephro Co., Ltd.702023-12-222025-04-04
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
Ketone ester - ADPKD
Phase 2UnknownUniversitair Ziekenhuis Brussel202023-11-012023-10-25
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet - Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases
Phase 2Enrolling by invitationTaipei Medical University Shuang Ho Hospital302023-05-012023-05-23
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Empagliflozin, Placebo - Polycystic Kidney, Autosomal Dominant
Phase 2Active not recruitingUniversity of Colorado, Denver502022-11-182026-05-01
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
PB - Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus
Phase 2CompletedMayo Clinic362022-09-012026-01-27
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
CAM2029, Placebo - Polycystic Liver Disease
Phase 2 / Phase 3Active not recruitingCamurus AB712022-06-282026-06-01
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Leuprorelin - Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
Phase 2RecruitingUniversity Medical Center Groningen362022-06-012022-11-04
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
GLPG2737, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2TerminatedLakefront Biotherapeutics NV662020-11-102024-08-22
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Pravastatin, sodium citrate - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedUniversity of Southern California12019-01-302025-08-06
Tolvaptan-Octreotide LAR Combination in ADPKD
Tolvaptan, Octreotide LAR, Placebo - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedMario Negri Institute for Pharmacological Research202018-12-122022-11-03
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Venglustat, Placebo - Polycystic Kidney, Autosomal Dominant
Phase 2 / Phase 3TerminatedGenzyme, a Sanofi Company4782018-10-042023-02-03
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Lixivaptan - Autosomal Dominant Polycystic Kidney Disease
Phase 2CompletedPalladio Biosciences312018-09-142022-12-05
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes
Phase 2CompletedBiogen1032017-12-262025-06-03
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
Tesevatinib, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD
Phase 2CompletedKadmon, a Sanofi Company802017-10-122023-02-06

Showing 20 of 50. Sign in to see all of them.

Narrower conditions

Polycystic Kidney, Autosomal Dominant (44)  ·  Polycystic liver disease (7)  ·  Kidney Diseases (4)  ·  Hepatomegaly (3)  ·  Liver Diseases (3)  ·  Diabetes Insipidus (2)  ·  Hypertension (2)  ·  Abdominal Pain (1)  ·  Diabetes Insipidus, Nephrogenic (1)  ·  Glomerulonephritis, IGA (1)  ·  Glomerulosclerosis, Focal Segmental (1)  ·  Multiple Pterygium Syndrome, Autosomal Dominant (1)  ·  Obesity (1)  ·  Renal Insufficiency (1)

Broader conditions

Abnormalities, Multiple (50)  ·  Ciliopathies (50)  ·  Congenital Abnormalities (50)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (50)  ·  Female Urogenital Diseases (50)  ·  Female Urogenital Diseases and Pregnancy Complications (50)  ·  Genetic Diseases, Inborn (50)  ·  Kidney Diseases, Cystic (50)  ·  Male Urogenital Diseases (50)  ·  Urogenital Diseases (50)  ·  Urologic Diseases (50)  ·  Kidney Diseases (46)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Digestive System Diseases (3)

Interventions

Tolvaptan (7)  ·  Sirolimus (5)  ·  XL647 (3)  ·  Metformin (2)  ·  Niacinamide (2)  ·  Tablets (2)  ·  empagliflozin (2)  ·  lanreotide (2)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1)  ·  Antihypertensive Agents (1)  ·  Atorvastatin (1)  ·  Diet (1)  ·  Everolimus (1)  ·  Leuprolide (1)  ·  MTOR Inhibitors (1)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (4)  ·  Mario Negri Institute for Pharmacological Research (3)  ·  Mayo Clinic (3)  ·  Radboud University Medical Center (3)  ·  University of Colorado, Denver (3)  ·  Federico II University (2)  ·  Kadmon, a Sanofi Company (2)  ·  A. Manzoni Hospital (1)  ·  Alan Yu, MB, BChir (1)  ·  Biogen (1)  ·  Calico Life Sciences LLC (1)  ·  Camurus AB (1)  ·  Cantonal Hospital Graubuenden (1)  ·  Genzyme, a Sanofi Company (1)  ·  Indiana University (1)

Countries

United States (28)  ·  Netherlands (10)  ·  Italy (8)  ·  Belgium (7)  ·  Spain (6)  ·  Germany (5)  ·  Japan (5)  ·  Canada (4)  ·  South Korea (4)  ·  Australia (3)  ·  China (3)  ·  Czechia (3)  ·  France (3)  ·  Poland (3)  ·  United Kingdom (3)

Top investigators

Frank Czerwiec, M.D., Ph.D. (2)  ·  Frederik Nevens, MD, PhD (2)  ·  Loes van Keimpema, MSc (2)  ·  Alan S Yu, MB, BChir (1)  ·  Alan Yu, M.B., B.Chir (1)  ·  Changlin Mei, MD (1)  ·  Curie Ahn, MD, PhD (1)  ·  Dana Miskulin, MD (1)  ·  Erling B Pedersen (1)  ·  Fouad Chebib, MD (1)  ·  Francesco Locatelli, MD (1)  ·  Frank Czerweic, MD (1)  ·  Frank Czerwiec, MD, PhD (1)

Results publications

PMID 39356039, PMID 41385299, PMID 21903984, PMID 37250503, PMID 38837240, PMID 41348481, PMID 22773240, PMID 26166166, PMID 26844873, PMID 26912555, PMID 27212247, PMID 28810844, PMID 28838955, PMID 32843370, PMID 33768205, PMID 34391872, PMID 36204243, PMID 36535535, PMID 36754009, PMID 37349694, PMID 37986188, PMID 38010035, PMID 40377984

NIH funding

2017 (2), 2014 (1), 2019 (1), R01DK131755 (1), R01DK138915 (1), R21DK104086 (1), R21DK107969 (1), UL1RR024150 (1)